Qualitative Concept – Page 74

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

1 year ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)

Sarepta’s ELEVIDYS Gaining Ground Amidst Anticipation for Expanded Label Approval

1 year ago talkbio0Tagged Age, Child, Commission, ELEVIDYS, Labels (device)

ELEVIDYS, Age, Muscular Dystrophy, Duchenne, Sarepta, Labels (device), Child

Novo-founded Orbis Solutions Cracks Macrocycle Synthesis Challenges, Secures $26 Million Funding

1 year ago talkbio0Tagged macrocycle 1

macrocycle 1

Blooming Potential: BlossomHill Secures $100M Series B Funding for Small Molecule Cancer & Autoimmune Treatments

1 year ago talkbio0

– BlossomHill Therapeutics, a biotech focusing on small-molecule drug design, has raised $100 million in a Series B financing round. – Led by Colt Ventures, the funding includes investors such as OrbiMed, Cormorant Asset Management, Vivo Capital, Hercules BioVentures Partners, and others. – Total capital raised by BlossomHill reaches $173 million after this round. – […]